| Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection T Hosaka, F Suzuki, M Kobayashi, Y Seko, Y Kawamura, H Sezaki, ... Hepatology 58 (1), 98-107, 2013 | 818 | 2013 |
| Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis RS Taylor, RJ Taylor, S Bayliss, H Hagström, P Nasr, JM Schattenberg, ... Gastroenterology 158 (6), 1611-1625. e12, 2020 | 808 | 2020 |
| Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma Y Kawamura, Y Arase, K Ikeda, Y Seko, N Imai, T Hosaka, M Kobayashi, ... Official journal of the American College of Gastroenterology| ACG 107 (2 …, 2012 | 308 | 2012 |
| Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b F Suzuki, H Sezaki, N Akuta, Y Suzuki, Y Seko, Y Kawamura, T Hosaka, ... Journal of Clinical Virology 54 (4), 352-354, 2012 | 129 | 2012 |
| The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040 T Ito, M Ishigami, B Zou, T Tanaka, H Takahashi, M Kurosaki, M Maeda, ... Hepatology international 15, 366-379, 2021 | 113 | 2021 |
| Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: An open-label, single-arm, multicenter, pilot study Y Honda, T Kessoku, Y Sumida, T Kobayashi, T Kato, Y Ogawa, ... BMC gastroenterology 17, 1-8, 2017 | 107 | 2017 |
| Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non‐alcoholic fatty liver disease and type 2 diabetes mellitus Y Seko, Y Sumida, S Tanaka, K Mori, H Taketani, H Ishiba, T Hara, ... Hepatology Research 47 (10), 1072-1078, 2017 | 105 | 2017 |
| Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease Y Sumida, K Kanemasa, S Imai, K Mori, S Tanaka, H Shimokobe, ... Journal of gastroenterology 50, 996-1004, 2015 | 94 | 2015 |
| The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study H Ishiba, Y Sumida, S Tanaka, M Yoneda, H Hyogo, M Ono, H Fujii, ... Journal of gastroenterology 53, 1216-1224, 2018 | 93 | 2018 |
| Effect of 12‐week dulaglutide therapy in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease and type 2 diabetes mellitus Y Seko, Y Sumida, S Tanaka, K Mori, H Taketani, H Ishiba, T Hara, ... Hepatology Research 47 (11), 1206-1211, 2017 | 93 | 2017 |
| Lower levels of insulin‐like growth factor‐1 standard deviation score are associated with histological severity of non‐alcoholic fatty liver disease Y Sumida, Y Yonei, S Tanaka, K Mori, K Kanemasa, S Imai, H Taketani, ... Hepatology research 45 (7), 771-781, 2015 | 93 | 2015 |
| Highly sensitive AFP‐L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre‐and postoperatively M Kobayashi, T Hosaka, K Ikeda, Y Seko, Y Kawamura, H Sezaki, ... Hepatology Research 41 (11), 1036-1045, 2011 | 92 | 2011 |
| Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis Y Seko, T Nishikawa, A Umemura, K Yamaguchi, M Moriguchi, K Yasui, ... Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 835-843, 2018 | 91 | 2018 |
| Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus Y Sumida, Y Seko, M Yoneda, ... Hepatology research 47 (4), 266-280, 2017 | 83 | 2017 |
| Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma N Iwai, K Yasui, A Tomie, Y Gen, K Terasaki, T Kitaichi, T Soda, ... International journal of oncology 53 (1), 237-245, 2018 | 81 | 2018 |
| Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B M Tanaka, F Suzuki, Y Seko, T Hara, Y Kawamura, H Sezaki, T Hosaka, ... Journal of gastroenterology 49, 470-480, 2014 | 73 | 2014 |
| The genetic backgrounds in nonalcoholic fatty liver disease Y Seko, K Yamaguchi, Y Itoh Clinical journal of gastroenterology 11, 97-102, 2018 | 72 | 2018 |
| Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials Y Seko, Y Sumida, K Sasaki, Y Itoh, H Iijima, T Hashimoto, S Ishii, ... Journal of gastroenterology 53, 140-151, 2018 | 71 | 2018 |
| Development of hepatocellular carcinoma in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease: association between PNPLA3 genotype and hepatocarcinogenesis … Y Seko, Y Sumida, S Tanaka, K Mori, H Taketani, H Ishiba, T Hara, ... Hepatology Research 47 (11), 1083-1092, 2017 | 71 | 2017 |
| Clearance of hepatitis B surface antigen during long-term nucleot (s) ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study T Hosaka, F Suzuki, M Kobayashi, Y Seko, Y Kawamura, H Sezaki, ... Journal of gastroenterology 48, 930-941, 2013 | 70 | 2013 |